Login

The perspective of the asthma/COPD community

Home > General public > The perspective of the asthma/COPD community

Personalised treatment

Asthma and Chronic obstructive pulmonary disease (COPD) are two of the most researched diseases, but progress in finding new, more effective treatments has been disappointing.

A solution could be to use personalised treatment. In other words, each person could get a medicine based on the specific type of asthma or COPD they have. This takes into account the fact that everyone is different, and medicines can work in people in different ways. Working out how to use personalised treatment in people with asthma or COPD could help people to find the best, most effective medicine for them more easily.

The NOVELTY study has the benefit of including a range of people and collecting many different types of information over time. This is important, as studying a variety of people will help us to understand the different types of asthma and COPD and how different treatments affect them.

Improving our understanding of the different types of asthma and COPD is an essential step towards making personalised treatment a reality.

The perspective of people with asthma and COPD

To help us improve healthcare for people with asthma and COPD, it is important to look at things from their point of view so that we can understand how they are affected by their condition. People with asthma or COPD might see things differently to their doctors, so by collecting information from both patients and doctors, we can get a full picture of what their disease is like.

In NOVELTY, people with asthma and/or COPD fill out different questionnaires using an online form every 3 months. This information that comes directly from patients is called a patient-reported outcome (PRO).

Also, NOVELTY was designed together with people affected by asthma and/or COPD. Read more about our patient advocates here.

Patient-reported outcomes

Getting the perspective of people with asthma and/or COPD is crucial in NOVELTY – watch this video to find out why.

19 PARTICIPATING COUNTRIESa
~12,000 ENROLLED PATIENTSa
80% OF PATIENTS HAVE SPIROMETRY DATAb

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study